Sen. Tom Cotton (R-Ark.) and Rep. Mike Gallagher (R-Wis.) announced plans to introduce a bill to reduce U.S. dependence on China manufacturing of pharmaceuticals.
The key restrictions outlined in the bill would go into effect in 2022, making the United States more resilient in the face of future pandemics. It’s a forward-looking measure to cut dependency on other countries for supplies of key pharmaceuticals that could be used to prevent or treat infections.
Specifically, the bill will track active pharmaceutical ingredients through an FDA registry and prohibit pharmaceutical purchases from China and products with active pharmaceutical ingredients created in China. It will also create transparency in the supply chain by instituting a country-of-origin label of all imported drugs, and provide economic incentives for manufacturing drugs and medical equipment in the United States.
‘Global Emergency’
The move to introduce the bill comes amid a growing number of infections in the United States of the CCP virus, commonly known as the novel coronavirus.Experts have long called for more decoupling between the United States and China in the area of strategic supplies.
“This is a giant wake-up call,” she said.
CCP Virus ‘Hell’
On March 4, Chinese state-run outlet Xinhua re-published a blog post titled, “With justice on our side, the world should thank China.”“Now the United States is in turmoil. More and more states have declared a state of emergency, while the whole country is extremely short on medical supply. A coronavirus epidemic is almost inevitable,” the article stated.
It went on to say that U.S. reliance on supply chains in China proves that the former needs the latter to contain the virus.
“Most facial masks in the U.S. market are made and imported from China. ... The majority of medicine in the U.S. is imported from other countries. ... If China bans exports to the United States, the latter will enter into hell caused by the coronavirus.”
Cotton and Gallagher’s initiative seeks to de-risk this supply chain.
‘Process Has Already Started’
On March 3, the Trump administration’s Coronavirus Task Force met with representatives of pharmaceutical and biotechnology companies at the White House. Trump said steps were already being taken to mitigate the public health risks of reliance on other countries for key drugs and equipment.“The coronavirus shows the importance of bringing manufacturing back to America so that we are producing, at home, the medicines and equipment and everything else that we need to protect the public’s health,” Trump said. “That process has already started.”
“We want to make certain things at home. We want to be doing our manufacturing at home. It’s not only done in China,” Trump said. “A lot of places make our different drugs and things that we need so badly.”
Trade expert Alan Tonelson praised the Trump administration’s efforts to reshore strategic manufacturing capacity.
“A U.S. economy heavily reliant on vital medicines and their ingredients from an increasingly hostile and secretive China is a devastating indictment of pre-Trump national security and public health policy,” Tonelson told The Epoch Times in an email.
“But the purely economic effects shouldn’t be overlooked either, as globalist leaders also encouraged the buildup of China as a huge global manufacturing hub, and thereby exposed Americans to the risk of shortages and other supply chain risks in a wide variety of critical products.”
The DPA allows the president to direct the production of private sector firms of critical manufactured goods to meet urgent national security needs.